Mechanisms of portal-systemic encephalopathy : a study using isolated liver and brain perfusion

Imperial Users onl

Generalizations of the Andrews-Bressoud Identities for the N=1N=1 Superconformal Model SM(2,4ν)SM(2,4\nu)

We present generalized Rogers-Ramanujan identities which relate the fermi and bose forms of all the characters of the superconformal model $SM(2,4\nu).$ In particular we show that to each bosonic form of the character there is an infinite family of distinct fermionic $q-$ series representations.Comment: 17 pages in harvmac, no figures, submitted as part of the proceedings of ``Physique et Combinatiore'' held at CIRM Luminy March 27-31, 199

Representing disease courses: An application of the Neurological Disease Ontology to Multiple Sclerosis Typology

The Neurological Disease Ontology (ND) is being developed to provide a comprehensive framework for the representation of neurological diseases (Diehl et al., 2013). ND utilizes the model established by the Ontology for General Medical Science (OGMS) for the representation of entities in medicine and disease (Scheuermann et al., 2009). The goal of ND is to include information for each disease concerning its molecular, genetic, and environmental origins, the processes involved in its etiology and realization, as well as its clinical presentation including signs and symptoms

The Analytic Theory of Matrix Orthogonal Polynomials

We give a survey of the analytic theory of matrix orthogonal polynomials.Comment: 85 page

On the Koplienko spectral shift function, I. Basics

We study the Koplienko Spectral Shift Function (KoSSF), which is distinct from the one of Krein (KrSSF). KoSSF is defined for pairs $A,B$ with (A-B)\in\calI_2, the Hilbert-Schmidt operators, while KrSSF is defined for pairs $A,B$ with (A-B)\in\calI_1, the trace class operators. We review various aspects of the construction of both KoSSF and KrSSF. Among our new results are: (i) that any positive Riemann integrable function of compact support occurs as a KoSSF; (ii) that there exist $A,B$ with (A-B)\in\calI_2 so $\det_2((A-z)(B-z)^{-1})$ does not have nontangential boundary values; (iii) an alternative definition of KoSSF in the unitary case; and (iv) a new proof of the invariance of the a.c. spectrum under \calI_1-perturbations that uses the KrSSF.Comment: Submitted to the Marchenko and Pastur birthday issue of Journal of Mathematical Physics, Analysis and Geometr

Rogers-Schur-Ramanujan type identities for the M(p,p′)M(p,p') minimal models of conformal field theory

We present and prove Rogers-Schur-Ramanujan (Bose/Fermi) type identities for the Virasoro characters of the minimal model $M(p,p').$ The proof uses the continued fraction decomposition of $p'/p$ introduced by Takahashi and Suzuki for the study of the Bethe's Ansatz equations of the XXZ model and gives a general method to construct polynomial generalizations of the fermionic form of the characters which satisfy the same recursion relations as the bosonic polynomials of Forrester and Baxter. We use this method to get fermionic representations of the characters $\chi_{r,s}^{(p,p')}$ for many classes of $r$ and $s.$Comment: 85 pages in harvmac with 16 figures. Stylistic revisions particularly in section 8 and appendix B and an additional proof added in appendix

Comprehensive Medication Management: Implications for the Patient and Pharmacist

Since 1979, state pharmacy practice laws have begun to allow pharmacists to provide advanced levels of care in collaboration with prescribers. These might be termed medication therapy management, collaborative practice, comprehensive medication management and other variations. Invariably, pharmacists working closely with prescribers and patients in care of chronic disease have achieved dramatic results including improvement in surrogate markers, decreased rates of secondary large organ disease, decreased mortality, decreased hospitalizations, and as a result decreased spending.1-28 This paper will discuss the profound impact of advanced practice models on patient care and the health care system, the current status of New York’s collaborative drug therapy management law, the comprehensive medication management proposal in Governor Cuomo’s fiscal year 2018 Budget bill, and its potential impact on morbidity and mortality when applied to chronic disease